Related Experiment Video

Updated: Aug 4, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation

Markus Meyer1, Darrell D Belke, Susanne U Trost

  • 1Department of Medicine, University of California, San Diego, La Jolla, CA 92093-0618, USA.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|June 8, 2004
PubMed

Insights

A novel antibody protein targeting phospholamban improved heart muscle contractility in mouse models. This approach enhances calcium handling, offering a potential therapy for heart failure and related cardiovascular diseases.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Biochemistry

Background:

  • Heart failure is often linked to impaired intracellular calcium handling.
  • Reduced activity of the sarcoplasmic reticulum calcium pump (SERCA) contributes to cardiac contractile dysfunction.
  • Phospholamban inhibits SERCA, making it a therapeutic target.

Purpose of the Study:

  • To investigate a recombinant antibody-based protein (PLN-Ab) targeting phospholamban.
  • To assess PLN-Ab's potential to improve cardiac function by modulating calcium handling.

Main Methods:

  • Developed a recombinant antibody protein (PLN-Ab) binding to phospholamban.
  • Utilized Fluorescence Resonance Energy Transfer (FRET) to study PLN-Ab interactions.
  • Expressed PLN-Ab in neonatal rat and adult mouse cardiac myocytes.
  • Administered adenovirus encoding PLN-Ab to diabetic mouse hearts for in vivo and ex vivo analysis.

Main Results:

  • PLN-Ab mimics phospholamban phosphorylation effects, enhancing calcium transient decay.
  • In vivo and ex vivo studies showed improved cardiac contractility after PLN-Ab delivery.
  • Adenovirus-mediated PLN-Ab expression in diabetic mouse hearts boosted contractile function.

Conclusions:

  • PLN-Ab effectively targets phospholamban to improve cardiac contractility.
  • In vivo expression of PLN-Ab offers a novel therapeutic strategy for heart failure.
  • Modulating calcium handling via PLN-Ab presents a promising avenue for cardiovascular disease treatment.

More Related Videos

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes07:32

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Published on: May 25, 2022

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...